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To the Editor 
We thank Dr. Keynan et al. (1) for their interest in and comments on our work. Dr. 
Keynan et al., make several noteworthy points. Although community-acquired 
pneumonia (CAP) is frequently described as the most prevalent pulmonary infection in 
HIV-infected patients following pneumocystis and tuberculosis, it is well known that 
the prevalence of these three pulmonary infections varies with geographic region (2). 
In Spain, the geographical area of our study, Legionella pneumophila is the third most 
frequent cause of CAP in HIV-infected patients requiring hospitalization after 
pneumococcal and viral pneumonia (3). We understand the point of view of Keynan et 
al. (1) that our results in non-advanced, virologically suppressed HIV-infected patients 
are similar to the results reported in the South Bronx Legionella outbreak (4). In line 
with our study, recent data from US surveillance and reporting systems indicate that 
the incidence of Legionella has increased, with the cities of New York, Maryland and 
Connecticut having the highest incidence in the US Northeast or Mid-Atlantic regions 
(5, 6). Of course, we cannot compare the incidence of Legionella with regions such as 
South Africa, where despite the high prevalence of HIV-infected adults, CAP caused by 
Legionella is uncommon (less than 2% of all adults with CAP) and undiagnosed mainly 
due to the high burden of tuberculosis and HIV co-infection (7) (approximately 50% of 
tuberculosis cases are HIV-infected) as concluded in the study by Wolter et al. (1). 
We totally agree with the observation of Keynan et al. (1) that our results cannot be 
applied to advanced patients, because of more the 80% of our cases had ˃200 CD4 
cell/mm3. In addition, more than half of our cases were virologically suppressed on 
antiretroviral therapy (ART), as is recognized among the limitations our study: “E
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though we included consecutive cases, 54% had virological suppression, and because 
of the small number of cases included, our results cannot be extrapolated to non-
suppressed HIV-infected patients”(8). We believe that these two issues as well as all 
our cases having received appropriate empiric antibiotic therapy provide clarification 
as to why our cohort of patients presented lower rates of admission to intensive care 
unit (ICU) and favorable outcomes.  
In conclusion, as it may be difficult to identify Legionella infection in regions with 
higher burdens of HIV and tuberculosis, such as South Africa, clinicians must make an 
effort to diagnose Legionella despite the uncommon presentation, given the higher 
associated mortality especially due to inadequate antibiotic therapy. Finally, our 
results can be applied to regions such as Europe, Australia and North America were 
most HIV-infected patients have high CD4 cell counts and are virologically suppressed 
on ART. 
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